Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kevin R. Jepson"'
Autor:
Krithika Muthuraman, Richard E. Higgs, Carl L. Hansen, Maren de Vries, Mark J. Mulligan, Kizzmekia S. Corbett, Ping Xiang, Nicole V. Johnson, Jory A. Goldsmith, Jason S. McLellan, John R. Mascola, Marissa H. Piper, Lucas Kraft, Jamie L. Blackbourne, Samuel J. Hinshaw, Davide Pellacani, Stefanie Žentelis, Christopher M. Wiethoff, Solmaz Sobhanifar, David R. Martinez, Franz J. Triana, Thomas P. Cujec, Barney S. Graham, Robert W. Cross, Ching-Lin Hsieh, Beverly A. Heinz, Denisa Foster, Ralph S. Baric, Sean A. Tycho, Jorg Hendle, David Collins, Eun Sung Yang, Ester Falconer, Daniel Wrapp, Andrew C. Adams, Roza Bidshahri, A. Pustilnik, Yuri Hwang, Adil Mohamed, Julian Davies, Yi Zhang, Patricia Brown-Augsburger, Bryan Edward Jones, Shawn J. Berens, Kevin R. Jepson, Bryan C. Barnhart, Kathryn Westendorf, Lingshu Wang, Viktoriya Borisevich, Meike Dittmann, Maia A. Smith, Deepa Balasubramaniam, Thomas W. Geisbert, Rodrigo Goya, Hayley M. Belli, Olubukola M. Abiona, Marie I. Samanovic
Publikováno v:
bioRxiv
Science Translational Medicine
Science Translational Medicine
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9583f7e9324500f23351af9888ed9e1d
https://pubmed.ncbi.nlm.nih.gov/33024963
https://pubmed.ncbi.nlm.nih.gov/33024963
Autor:
Mark J. Mulligan, Kizzmekia S. Corbett, Marissa H. Piper, Nicole V. Johnson, Jory A. Goldsmith, Roza Bidshahri, Carl L. Hansen, Robert W. Cross, Daniel Wrapp, A. Pustilnik, Yuri Hwang, Julian Davies, Adil Mohamed, Kathryn Westendorf, Beverly A. Heinz, Olubukola M. Abiona, Lucas Kraft, Jamie L. Blackbourne, Andrew C. Adams, Marie I. Samanovic, Samuel J. Hinshaw, Bryan Edward Jones, Sean A. Tycho, Christopher M. Wiethoff, Shawn J. Berens, Krithika Muthuraman, Stefanie Zentelis, Thomas W. Geisbert, Richard E. Higgs, Ralph S. Baric, Lingshu Wang, Jorg Hendle, Maia A. Smith, Hayley M. Belli, Meike Dittmann, Deepa Balasubramaniam, Solmaz Sobhanifar, Rodrigo Goya, Denisa Foster, John R. Mascola, Viktoriya Borisevich, Thomas P. Cujec, Barney S. Graham, Ping Xiang, Jason S. McLellan, Davide Pellacani, David R. Martinez, Maren de Vries, Patricia Brown-Augsburger, Franz J. Triana, David Collins, Ester Falconer, Kevin R. Jepson, Bryan C. Barnhart, Ching-Lin Hsieh
Publikováno v:
Science Translational Medicine
LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.
A monoclonal for SARS-CoV-2 Among the most promising therapeutic options for individuals with coro
A monoclonal for SARS-CoV-2 Among the most promising therapeutic options for individuals with coro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::910c20bb8473b8eebf9a1ddc2b988951
https://doi.org/10.1101/2020.09.30.318972
https://doi.org/10.1101/2020.09.30.318972
